We’re pleased to announce the initiation of our Phase 2 clinical study evaluating crinecerfont in pediatric patients aged 3 months to 4 years with classic CAH. There is a significant need for additional treatment options, as management typically begins early in life an continues throughout childhood.

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-initiates-phase-2-study-crinecerfont